The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Inappropriate p53 activation during development induces features of CHARGE syndrome
Abstract
CHARGE syndrome is a multiple anomaly disorder in which patients present with a variety of phenotypes, including ocular coloboma, heart defects, choanal atresia, retarded growth and development, genitourinary hypoplasia and ear abnormalities. Despite 70–90% of CHARGE syndrome cases resulting from mutations in the gene CHD7, which encodes an ATP-dependent chromatin remodeller, the pathways underlying the diverse phenotypes remain poorly understood. Surprisingly, our studies of a knock-in mutant mouse strain that expresses a stabilized and transcriptionally dead variant of the tumour-suppressor protein p53 (p5325,26,53,54), along with a wild-type allele of p53 (also known as Trp53), revealed late-gestational embryonic lethality associated with a host of phenotypes that are characteristic of CHARGE syndrome, including coloboma, inner and outer ear malformations, heart outflow tract defects and craniofacial defects. We found that the p5325,26,53,54 mutant protein stabilized and hyperactivated wild-type p53, which then inappropriately induced its target genes and triggered cell-cycle arrest or apoptosis during development. Importantly, these phenotypes were only observed with a wild-type p53 allele, as p5325,26,53,54/− embryos were fully viable. Furthermore, we found that CHD7 can bind to the p53 promoter, thereby negatively regulating p53 expression, and that CHD7 loss in mouse neural crest cells or samples from patients with CHARGE syndrome results in p53 activation. Strikingly, we found that p53 heterozygosity partially rescued the phenotypes in Chd7-null mouse embryos, demonstrating that p53 contributes to the phenotypes that result from CHD7 loss. Thus, inappropriate p53 activation during development can promote CHARGE phenotypes, supporting the idea that p53 has a critical role in developmental syndromes and providing important insight into the mechanisms underlying CHARGE syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Defective p53 activity is increasingly implicated in the etiology of several additional uncommon genetic disorders, such as Diamond–Blackfan anemia (DBA), CHARGE syndrome, and ATR-Seckel syndrome.173–175”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [175]
In the citing paper
“In various mouse models, p53 hyperactivity has been shown to phenocopy many developmental diseases, including features of CHARGE syndrome (acronym: coloboma, heart defects, atresia choanae, growth retardation, genital abnormalities, and ear abnormalities) [164].”
From The TP53 tumor suppressor gene: From molecular biology to clinical investigations (2025) · cites this paper as [164]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Kenzelmann Broz, D., Spano Mello, S., Bieging, K. T., Jiang, D., Dusek, R. L., Brady, C. A., Sidow, A., & Attardi, L. D. (2013) · Genes & Development · doi:10.1101/gad.212282.112 · Cited by 443
Self-citationKeeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401912 · Cited by 352
Epigenomic annotation of enhancers predicts transcriptional regulators of human neural crest
Rada-Iglesias, A., Bajpai, R., Prescott, S., Brugmann, S. A., Swigut, T., & Wysocka, J. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.07.006 · Cited by 314
Self-citationTumor suppression and normal aging in mice with constitutively high p53 activity
Mendrysa, S. M., O'Leary, K. A., McElwee, M. K., Michalowski, J., Eisenman, R. N., Powell, D. A., & Perry, M. E. (2006) · Genes & Development · doi:10.1101/gad.1378506 · Cited by 210
Research works printed but not linked: 30
- Davenport, S. L. H., Hefner, M. A. & Mitchell, J. A. The spectrum of clinical features in CHARGE syndrome. Clin. Genet. 29, 298–310 (1986) · DOI · Paper page
- Jongmans, M. C. J. et al. CHARGE syndrome: the phenotypic spectrum of mutations in the CHD7 gene. J. Med. Genet. 43, 306–314 (2006) · DOI · Paper page
- Brady, C. A. et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571–583 (2011) · DOI · Paper page
- Johnson, T. M., Hammond, E. M., Giaccia, A. & Attardi, L. D. The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nature Genet. 37, 145–152 (2005) · DOI
- Brock, K. E., Mathiason, M. A., Rooney, B. L. & Williams, M. S. Quantitative analysis of limb anomalies in CHARGE syndrome: correlation with diagnosis and characteristic CHARGE anomalies. Am. J. Med. Genet. A. 123A, 111–121 (2003) · DOI
- Zentner, G. E., Layman, W. S., Martin, D. M. & Scacheri, P. C. Molecular and phenotypic aspects of CHD7 mutation in CHARGE syndrome. Am. J. Med. Genet. A. 152A, 674–686 (2010) · DOI · Paper page
- Lalani, S. R. et al. Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype–phenotype correlation. Am. J. Hum. Genet. 78, 303–314 (2006) · DOI · Paper page
- Ragan, D. C., Casale, A. J., Rink, R. C., Cain, M. P. & Weaver, D. D. Genitourinary anomalies in the CHARGE association. J. Urol. 161, 622–625 (1999) · DOI
- Inoue, H. et al. Successful cord blood transplantation for a CHARGE syndrome with CHD7 mutation showing DiGeorge sequence including hypoparathyroidism. Eur. J. Pediatr. 169, 839–844 (2010) · DOI
- Corsten-Janssen, N. et al. The cardiac phenotype in patients with a CHD7 mutation. Circ. Cardiovasc. Genet. 6, 248–254 (2013) · DOI
- Rinon, A. et al. p53 coordinates cranial neural crest cell growth and epithelial–mesenchymal transition/delamination processes. Development 138, 1827–1838 (2011) · DOI
- Armstrong, J. F., Kaufman, M. H., Harrison, D. J. & Clarke, A. R. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5, 931–936 (1995) · DOI · Paper page
- Lengner, C. J. et al. Osteoblast differentiation and skeletal development are regulated by Mdm2–p53 signaling. J. Cell Biol. 172, 909–921 (2006) · DOI · Paper page
- Sanlaville, D. et al. Phenotypic spectrum of CHARGE syndrome in fetuses with CHD7 truncating mutations correlates with expression during human development. J. Med. Genet. 43, 211–217 (2006) · DOI · Paper page
- Legendre, M. et al. Antenatal spectrum of CHARGE syndrome in 40 fetuses with CHD7 mutations. J. Med. Genet. 49, 698–707 (2012) · DOI
- Veprintsev, D. B. & Fersht, A. R. Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res. 36, 1589–1598 (2008) · DOI
- Bajpai, R. et al. CHD7 cooperates with PBAF to control multipotent neural crest formation. Nature 463, 958–962 (2010) · DOI · Paper page
- Schnetz, M. P. et al. CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression. PLoS Genet. 6, e1001023 (2010) · DOI · Paper page
- Bosman, E. A. et al. Multiple mutations in mouse Chd7 provide models for CHARGE syndrome. Hum. Mol. Genet. 14, 3463–3476 (2005) · DOI · Paper page
- Hurd, E. et al. Loss of Chd7 function in gene-trapped reporter mice is embryonic lethal and associated with severe defects in multiple developing tissues. Mamm. Genome 18, 94–104 (2007) · DOI · Paper page
- Adams, M. E. et al. Defects in vestibular sensory epithelia and innervation in mice with loss of Chd7 function: implications for human CHARGE syndrome. J. Comp. Neurol. 504, 519–532 (2007) · doi:10.1002/cne.21460
- Morimoto, A. K. et al. Absent semicircular canals in CHARGE syndrome: radiologic spectrum of findings. AJNR Am. J. Neuroradiol. 27, 1663–1671 (2006)
- Mendrysa, S. M. et al. mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol. Cell. Biol. 23, 462–472 (2003) · DOI · Paper page
- Balow, S. A. et al. Knockdown of fbxl10/kdm2bb rescues chd7 morphant phenotype in a zebrafish model of CHARGE syndrome. Dev. Biol. 382, 57–69 (2013) · DOI
- Corsten-Janssen, N. et al. More clinical overlap between 22q11.2 deletion syndrome and CHARGE syndrome than often anticipated. Mol. Syndromol. 4, 235–245 (2013) · doi:10.1159/000351127
- Jones, N. C. et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nature Med.14. 125–133 (2008) · DOI · Paper page
- Sato, T. & Bartunkova, S. Analysis of embryonic vascular morphogenesis. Methods Mol. Biol. 137, 223–233 (2000)
- Ovchinnikov, D. Alcian blue/alizarin red staining of cartilage and bone in mouse. Cold Spring Harb. Protoc. http://dx.doi.org/10.1101/pdb.prot5170 (March 2009) · DOI
- Hurd, E. A., Poucher, H. K., Cheng, K., Raphael, Y. & Martin, D. M. The ATP-dependent chromatin remodeling enzyme CHD7 regulates pro-neural gene expression and neurogenesis in the inner ear. Development 137, 3139–3150 (2010) · DOI
- Lane, D. et al. Epitope analysis of the murine p53 tumour suppressor protein. Oncogene 12, 2461–2466 (1996)
Cited by
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
Ubiquitylation at the crossroads of development and disease
Rape, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.83 · Cited by 614
A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer
Mello, S. S., Valente, L. J., Raj, N., Seoane, J. A., Flowers, B. M., McClendon, J., Bieging-Rolett, K. T., Lee, J., Ivanochko, D., Kozak, M. M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.007 · Cited by 179
Self-citationMarie, C., Clavairoly, A., Frah, M., Hmidan, H., Yan, J., Zhao, C., Van Steenwinckel, J., Daveau, R., Zalc, B., Hassan, B., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802620115 · Cited by 103
Self-citationp53: key conductor of all anti-acne therapies
Melnik, B. C. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1297-2 · Cited by 78
Metadata
- Authors
- Van Nostrand, J. L., Brady, C. A., Jung, H., Fuentes, D. R., Kozak, M. M., Johnson, T. M., Lin, C.-Y., Lin, C.-J., Swiderski, D. L., Vogel, H., Bernstein, J. A., Attié-Bitach, T., Chang, C.-P., Wysocka, J., Martin, D. M., & Attardi, L. D.
- Venue
- Nature
- Published
- 2014-08-03
- Volume
- 514
- Issue
- 7521
- Pages
- 228-232
- ISSN
- 0028-0836
- 1476-4687
- Cited by
- 143
- References
- 7
- Language
- en
- Licence
- www.springer.com/tdm (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.